Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 92Breast Neoplasms 69Prostatic Neoplasms 33Triple Negative Breast Neoplasms 32Neoplasms 26Fallopian Tube Neoplasms 25Neoplasm Metastasis 21Endometrial Neoplasms 19Pancreatic Neoplasms 18Small Cell Lung Carcinoma 13Carcinoma, Ovarian Epithelial 12Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Sarcoma 9Recurrence 9Lung Neoplasms 9Fanconi Anemia, Complementation Group D1 9Squamous Cell Carcinoma of Head and Neck 8Glioma 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Colorectal Neoplasms 6Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Solid Tumors 4Osteosarcoma 4

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
PSR Ovarian Cancer With a BRCA Mutation × olaparib × Clear all
NCT03063710 2018-05-17

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

AstraZeneca

No longer available
Gynecologic

PSR Ovarian Cancer With a BRCA Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡